Invasion and Metastasis Lab
@Timpson_Lab
Our lab uses intravital imaging approaches to pinpoint critical events that drive tumour invasion and metastasis | @GarvanInstitute @KinghornCancer @UNSW
Our latest publication in @ScienceAdvances is officially out! Here, we target the NPY/NPY1R signalling axis to lessen metastatic burden of mutant p53-dependent #PancreaticCancer 🔬👩🏼🔬 Check it out here: science.org/doi/10.1126/sc… @GarvanInstitute @Timpson_Lab
Join us in our mission to save lives and transform the future of pancreatic cancer treatment. 💜 Click here to find out more: ow.ly/rjK750W6Jr0 #PancreaticCancer #PancreaticCancerAwareness #garvan #PurpleForAPurpose #FightPancreaticCancer #PurpleOurWorld
We’re excited to share news from the @ampliatx ACCENT trial: one patient with advanced pancreatic cancer showed no remaining cancer cells after treatment. This complete response is extremely rare in this aggressive cancer type.
$ATX UPDATE | #Amplia has today announced that a patient from ACCENT clinical trial in advanced #pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the #ASX release: bit.ly/ATX_pCR
$ATX | #Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release: bit.ly/ATX_SecondCR #pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
Did you catch this summary of the latest results from Amplia's ACCENT clinical trial in Small Caps this week? Take a look: bit.ly/ATX-SmallCaps-… $ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #innovation
$ATX UPDATE | #Amplia has today announced that a patient from ACCENT clinical trial in advanced #pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the #ASX release: bit.ly/ATX_pCR
#Amplia has made headlines today following the announcement of a “pathological complete response” in an advanced #pancreaticcancer patient today. Biotech journalist Tim Boreham noted that Amplia shares had soared almost 50% following the news. Take a look: bit.ly/ATX-Stockhead_…
Integrins provide a bridge between cancer cells and the #ECM, playing a role in every stage of disease progression. 🌉 Drs. James Conway & Johanna Ivaska reveal the importance of integrin phosphorylation for cancer cell invasion. @NatureCellBio 🔗 go.nature.com/3Sm35ex
$ATX | #Amplia has today announced that trial initiation activities for the planned pancreatic cancer trial in the US have begun. Read the ASX release: bit.ly/ATX-US-Trial #pancreaticcancer #clinicaltrial #drugdiscovery #innovation #cancertreatment
Check out our latest work on @7NewsSydney 🎥 Here, we report on targeting the NPY/NPY1R signalling axis to lessen #PancreaticCancer metastasis🔬👩🏼🔬 @GarvanInstitute Check it out here: youtu.be/TfBmrQ71Rq4?si…
📢 Hunter Meeting 2025 - Abstract submissions close on Friday 14th February 2025, 5pm AEST! The Hunter Meeting promises a fabulous line-up of international and national speakers in 2025. Submit your abstract and register to attend! Link: huntermeeting.org.au/abstract-submi…
Want to join our lab and contribute to world-class cancer research in Sydney? We are looking for a new research assistant! 🔬🧫 Apply here: seek.com.au/job/81805571?t…
Today - on #WorldCancerDay - we're grateful to our research collaborators, whose expertise and dedication make our clinical trials possible. Equal gratitude goes to the trial participants, and their families, who share our hope of improving outcomes for patients. #ATX #Amplia
1/Delighted to announce the newest paper from our lab, “Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage”, is out today in @NatureCellBio, nature.com/articles/s4155….
Congratulations to Dr Brooke Pereira on receiving a Fulbright Future Scholarship. Her work in pancreatic cancer research Garvan will benefit from this international opportunity. #FulbrightScholar #CancerResearch
Congratulations to CCB’s @dr_phil_gregory, @QuentenSchwarz and @TMEM_Samuel, who have been awarded @NHMRC Ideas Grant funding for 2025. Well done!
brnw.ch/21wPsyJ Five UniSA projects awarded $5mill in @NHMRC grants announced today are set to improve cancer treatment, & help people prioritise their time building health
I'm very pleased to share that I have received a NHMRC Ideas grant to explore targeting fibrosis in combination with chemotherapy to improve treatment efficacy in pancreatic cancer. Also a big thank you to the CI/AI team - cant wait to get started! @Timpson_Lab @GarvanInstitute
We are pleased to share Garvan researchers have secured six highly competitive NHMRC Ideas and Development Grants! Congratulations Drew Neavin, Brooke Pereira, Andre Reis, Daniel Christ, Marcia Munoz and Kendelle Murphy.
VIDEO | #Amplia CEO & MD Dr Chris Burns and COO Dr Rhiannon Jones discuss the significance of Amplia’s latest clinical data from the ACCENT trial, and what investors can expect from Amplia in 2025. Take a look: youtu.be/as23w84i1cs $ATX #clinicaltrial #pancreaticcancer #pharma
A $3.75 million grant from the Institute is supporting an innovative ‘personalised medicine framework’ that is giving hope to people with pancreatic cancer. Learn more about its progress: brnw.ch/21wPnHP
Congratulations to Jan Mumford, our well-deserved recipient of the 2024 John Zalcberg AO Award for Excellence in AGITG Research #AGITG24